GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men

NCT02170324 on ClinicalTrials.gov · last registry update 2017-01-18

A small phase 4 — 20 participants, against a typical 75. The sponsor logged completion for July 2015. Primary outcome, as filed: The expression of brown adipose related genes in subcutaneous white adipose tissue. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Xiang Guang-da
Sponsor type: Other
Enrollment: 20
Started: 2014-06
Primary completion: 2015-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The expression of brown adipose related genes in subcutaneous white adipose tissue

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.